Pfizer reported a sharp drop in fourth‑quarter sales as demand for its COVID‑19 vaccine and antiviral drug Paxlovid continues to wane. The company posted a 12% decline in revenue, falling short of analysts’ expectations and signaling a broader slump in the pandemic‑era drug market and investors in the U.S. market.

With global vaccination rates plateauing and new variants offering limited protection, Pfizer’s earnings pressure mounts. Investors now scrutinize the company’s shift toward oncology and rare‑disease portfolios, hoping to offset the erosion in its flagship COVID‑19 products and stabilize long‑term cash flow and investors in the U.S. market.

Analysts warn that the decline could trigger a reevaluation of Pfizer’s valuation multiples, while the company may accelerate licensing deals to diversify revenue streams. Market watchers should monitor upcoming earnings calls for guidance on vaccine pipeline updates and potential cost‑cutting measures that could reshape the firm’s strategic outlook and analysts in the next quarter.